The Opthalmics Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter opthalmics partnering deals. The majority of deals are discovery, preclinical or development stage whereby the licensee obtains a right or an option right t- license the licensors opthalmics technology. These deals tend t- be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest opthalmics deals and contracts announced in the healthcare sectors.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight int- the negotiation process in terms of what you can expect t- achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases d- not.
The initial chapters of this report provide an orientation of opthalmics dealmaking and business activities.
Chapter 1 provides an introduction t- the report.
Chapter 2 provides an overview of the trends in opthalmics dealmaking since 2009covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of developmen.
Chapter 3 provides a review of the leading opthalmics deals since 2009. Deals are listed by headline value, signed by bigpharma and bigbiotech, most active bigpharma/bigbiotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access t- the contract.
Chapters 4 and 5 provide a comprehensive listing of the top 50 bigpharma and bigbiotech companies with a brief summary followed by a comprehensive listing of opthalmics deals, as well as contract documents available in the public domain. Each deal title links via Weblink t- an online version of the deal record and where available, the contract document, providing easy access t- each contract document on demand.
Chapter 6 provides comprehensive access t- all opthalmics deals since 2009 where a deal contract is available, providing the user with direct access t- contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink t- an online version of the deal record contract document, providing easy access t- each contract document on demand.
Chapter 7 provides a comprehensive directory of all opthalmics partnering deals by specific therapeutic target announced since 2009. The chapter is organized by specific opthalmics therapeutic target. Each deal title links via Weblink t- an online version of the deal record and where available, the contract document, providing easy access t- each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all opthalmics partnering deals signed and announced since 2009. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink t- an online version of the deal record and where available, the contract document, providing easy access t- each contract document on demand.
The report als- includes numerous tables and figures that illustrate the trends and activities in opthalmics partnering and dealmaking since 2009.
In conclusion, this report provides everything a prospective dealmaker needs t- know about partnering in the research, development and commercialization of opthalmics technologies and products.
Opthalmics Partnering Terms and Agreements provides the reader with the following key benefits:
- In-depth understanding of opthalmics deal trends since 2009
- Access opthalmics deal headline, upfront, milestone and royalty data
- Research hundreds of actual contracts between opthalmics partner companies
- Comprehensive access t- over 1500 links t- actual opthalmics deals entered int- by the world’s biopharma companies
- Indepth review of dental deals entered int- by the leading fifty bigpharma companies
- Benchmark the key deal terms companies have agreed in previous deals
- Identify key terms under which companies partner opthalmics opportunities
- Uncover companies actively partnering opthalmics opportunities
Opthalmics Partnering Terms and Agreements is intended t- provide the reader with an in-depth understanding and access t- opthalmics trends and structure of deals entered int- by leading companies worldwide.
OpthalmicsPartnering Terms and Agreements includes:
- Trends in opthalmics dealmaking in the biopharma industry since 2009
- Analysis of opthalmics deal structure
- Access t- headline, upfront, milestone and royalty data
- Access t- hundreds of opthalmics deal contract documents
- Comprehensive access t- over 350 opthalmics deal records
- The leading opthalmics deals by value since 2009
- Most active opthalmics dealmakers since 2009
In Opthalmics Partnering Terms and Agreements, available deals and contracts are listed by:
- Headline value - Upfront payment value
- Royalty rate value - Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
Each deal title links via Weblink t- an online version of the deal record and where available, the contract document, providing easy access t- each contract document on demand.
Spanning over 605 pages, “Ophthalmics Partnering Terms & Agreements” report covering the Trends in ophthalmics dealmaking, Leading ophthalmics deals, Bigpharma opthalmics deals, Big biotech ophthalmics deals, Ophthalmics partnering contracts directory, Ophthalmics dealmaking by therapeutic target, Appendices. The report covered companies are - Anika Therapeutics, Biocon, Enzo Biochem, Gilead Sciences, Isis Pharmaceuticals, Nektar Therapeutics, PDL BioPharma, Regeneron Pharmaceuticals
Know more about this report at : http://mrr.cm/ZWb
About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.
Mr. Amitava Sen
Vice President - Sales & Marketing
Market Research Reports, Inc.
Tel USA: +1-302-703-7787
Tel India: +91-80-26860858
For Business and Industry News visit: http://www.marketresearchtimes.com